What's happening with jaguar health's stock?
Jaguar Health's stock price gains accelerated in recent days, following the company's announcement on Jan. 6 that it began a 28-day preclinical toxicology and safety study in dogs for lechlemer, a plant-based drug candidate for the relief of diarrhea from cholera.
Is jaguar health in compliance with the NASDAQ bid price requirement?
Jaguar Health, Inc. on January 22, 2021 announced that on January 21, 2021 the Company received formal notice that Jaguar has regained compliance with the bid price requirement, as required by the decision of the Nasdaq Hearings Panel (the "Panel") dated October 28, 2020 (the "Decision").
What is the business model of jaguar health?
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. Jaguar Health develops pharmaceuticals derived from plants to treat GI dysfunction in adults and canines.
Does jaguar health have another large profit opportunity with Crofelemer?
Thus, Jaguar Health would likely have another large profit opportunity with crofelemer, if it's shown to be effective and safe in clinical trials. This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service.
Why did Jaguar Health stock drop so much?
Jaguar Health (JAGX) stock fell amid panic selling after the company announced a 1-for-3 reverse stock split, which was approved by majority of common stock shareholders in December 2020.
What happened to Jaguar Health Inc?
As previously announced, the merger of Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. (Napo) became effective July 31, 2017 (Merger), at which point Jaguar Animal Health's name changed to Jaguar Health, Inc.
Will Jaguar Health stock go up?
Jaguar Health Inc quote is equal to 0.325 USD at 2022-06-25. Based on our forecasts, a long-term increase is expected, the "JAGX" stock price prognosis for 2027-06-16 is 0.921 USD. With a 5-year investment, the revenue is expected to be around +183.44%. Your current $100 investment may be up to $283.44 in 2027.
Is Jaguar health a good stock to invest in?
The 2 analysts offering 12-month price forecasts for Jaguar Health Inc have a median target of 5.88, with a high estimate of 6.75 and a low estimate of 5.00. The median estimate represents a +1,353.13% increase from the last price of 0.40.
What happened with Jaguar stock?
Over the past few years, on a split-adjusted basis, JAGX stock has imploded, plunging from more than $1,000 per share to just $3.21 now. However, the ailing company has looked a little healthier at the beginning of 2021. JAGX stock has leapt back from under a dollar per share to its current level.
Who is JAGX merging with 2021?
The Merger of Jaguar Animal Health and Napo Pharmaceuticals is Effective. The Combined Company's New Name is Jaguar Health, Inc.
Will Bionano Genomics stock go up?
Stock Price Forecast The 3 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 8.00, with a high estimate of 12.00 and a low estimate of 6.00. The median estimate represents a +396.89% increase from the last price of 1.61.
Is ViewRay a good stock to buy?
ViewRay has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
What does Jaguar Health Inc do?
Jaguar Health, Inc. is a commercial stage pharmaceutical company. The Company is focused on developing plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with gastrointestinal (GI) distress, including chronic and debilitating diarrhea.
What is NAKD stock?
Cenntro Electric Group Limited (NASDAQ: NAKD), a leading EV technology company with advanced, market-validated electric commercial vehicles, today announced that its trading symbol on the Nasdaq Capital... NAKD : 2.61 (-14.98%)
Should I buy or sell Jaguar Health stock right now?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last twelve months. There are currently 1 buy rating...
What is Jaguar Health's stock price forecast for 2022?
1 brokers have issued 1-year price targets for Jaguar Health's stock. Their JAGX stock forecasts range from $5.00 to $5.00. On average, they expect...
How has Jaguar Health's stock price performed in 2022?
Jaguar Health's stock was trading at $1.04 at the start of the year. Since then, JAGX stock has decreased by 67.2% and is now trading at $0.3412....
When is Jaguar Health's next earnings date?
Jaguar Health is scheduled to release its next quarterly earnings announcement on Friday, August 12th 2022. View our earnings forecast for Jaguar...
How were Jaguar Health's earnings last quarter?
Jaguar Health, Inc. (NASDAQ:JAGX) issued its quarterly earnings data on Tuesday, May, 10th. The biotechnology company reported ($0.40) earnings per...
When did Jaguar Health's stock split? How did Jaguar Health's stock split work?
Shares of Jaguar Health reverse split on the morning of Wednesday, September 8th 2021. The 1-3 reverse split was announced on Wednesday, September...
Who are Jaguar Health's key executives?
Jaguar Health's management team includes the following people: Ms. Lisa A. Conte , Founder, CEO, Pres & Director (Age 63, Pay $722.54k) Mr. Jona...
Who are some of Jaguar Health's key competitors?
Some companies that are related to Jaguar Health include Greenwich LifeSciences (GLSI) , Evelo Biosciences (EVLO) , Daré Bioscience (DARE) , Sa...
What other stocks do shareholders of Jaguar Health own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Jaguar Health investors own include Biocept (BIOC) , Sorr...
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under the name Canalevia™-CA2, for treatment of EID in dogsSAN FRANCISCO, CA / ACCESSWIRE / February 16, 2022 / Jaguar Health, Inc.
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business modelSAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health (NASDAQ:JAGX) and Napo Therapeutics S., an Italian corporation established by Jaguar Health in Milan, Italy, today announced that Napo Therapeutics has been granted Small and Medium Enterprise (SME) designation by the European Medicines Agency (EMA)..
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrheaSAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc.
How many European investors did Jaguar Health have in 2020?
In December of 2020, Jaguar Health spoke to around 150 European institutional investors in four countries and six cities. The purpose was to find a SPAC to help finance its Napo Pharmaceuticals EU program.
Is Jaguar Health delisted?
In October of 2020, Jaguar Health received notification from Nasdaq that the company needed to comply with a minimum bid price requirement (via Street Insider ). Jaguar Health is not being de listed at this time.
About Jaguar Health
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. The firm focuses on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea.
Jaguar Health (NASDAQ:JAGX) Frequently Asked Questions
1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Jaguar Health in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Jaguar Health stock. View analyst ratings for Jaguar Health or view top-rated stocks.
JAGX Stock Overview
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea.
Valuation
Is Jaguar Health undervalued compared to its fair value and its price relative to the market?
Future Growth
How is Jaguar Health forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Dividend
What is Jaguar Health current dividend yield, its reliability and sustainability?
Management
How experienced are the management team and are they aligned to shareholders interests?
Ownership
Who are the major shareholders and have insiders been buying or selling?
Is Jaguar Health stock up?
Jaguar Health's stock price is up a stunning 2,062% since its lows on Nov. 16. Investors have bid up the healthcare stock after management announced its plan to develop and commercialize crofelemer, a new drug aimed at helping people with inflammatory diarrhea, including those who have recovered from COVID-19 but are still experiencing symptoms.
Is Jaguar Health a plant based drug?
6 that it began a 28-day preclinical toxicology and safety study in dogs for lechlemer, a plant-based drug candidate for the relief of diarrhea from cholera.
